文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

脂蛋白(a)与 2 型糖尿病患者糖尿病肾病的关系。

Association between Lipoprotein(a) and diabetic nephropathy in patients with type 2 diabetes.

机构信息

Department of Endocrinology, The First Affiliated Hospital of Xi'an JiaoTong University, Xi'an, Shaanxi, China.

Med-X Institute, Center for Immunological and Metabolic Diseases, The First Affiliated Hospital of Xi'an JiaoTong University, Xi'an, Shaanxi, China.

出版信息

Front Endocrinol (Lausanne). 2024 Jan 15;14:1337469. doi: 10.3389/fendo.2023.1337469. eCollection 2023.


DOI:10.3389/fendo.2023.1337469
PMID:38288472
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10822945/
Abstract

BACKGROUND: Diabetic nephropathy (DN) is one of the most prevalent and severe microvascular complications of type 2 diabetes (T2DM). However, little is currently known about the pathogenesis and its associated risk factors in DN. The present study aims to investigate the potential risk factors of DN in patients with T2DM. METHODS: A total of 6,993 T2DM patients, including 5,089 participants with DN and 1,904 without DN, were included in this cross-sectional study. Comparisons between the two groups (DN vs. non-DN) were carried out using Student's t-test, Mann-Whitney U-test, or Pearson's Chi-squared test. Spearman's correlation analyses were performed to assess the correlations of serum lipids and indicators of renal impairment. Logistic regression models were applied to assess the relationship between blood lipid indices and the presence of DN. RESULTS: T2DM patients with DN were older, and had a longer duration of diagnosed diabetes compared to those without DN. Of note, the DN patients also more likely develop metabolic disorders. Among all serum lipids, Lipoprotein(a) [Lp(a)] was the most significantly correlated indicators of renal impairment. Moreover, univariate logistic regression showed that elevated Lp(a) level was associated with an increased risk of DN. After adjusted for confounding factors, including age, gender, duration of T2DM, BMI, SBP, DBP and lipid-lowering drugs usage, Lp(a) level was independently positively associated with the risk of DN [odds ratio (OR):1.115, 95% confidence interval (CI): 1.079-1.151, =6.06×10]. CONCLUSIONS: Overall, we demonstrated that serum Lp(a) level was significantly positively associated with an increased risk of DN, indicating that Lp(a) may have the potential as a promising target for the diagnosis and treatment of diabetic nephropathy.

摘要

背景:糖尿病肾病(DN)是 2 型糖尿病(T2DM)最常见和最严重的微血管并发症之一。然而,目前对于 DN 的发病机制及其相关危险因素知之甚少。本研究旨在探讨 T2DM 患者发生 DN 的潜在危险因素。

方法:本横断面研究共纳入 6993 例 T2DM 患者,其中 5089 例患者患有 DN,1904 例患者未患有 DN。采用 Student's t 检验、Mann-Whitney U 检验或 Pearson's Chi-squared 检验对两组(DN 与非 DN)进行比较。采用 Spearman 相关分析评估血清脂质和肾功能损害指标之间的相关性。采用 logistic 回归模型评估血脂指标与 DN 发生的关系。

结果:与非 DN 患者相比,DN 患者年龄更大,确诊糖尿病的病程更长。值得注意的是,DN 患者更易发生代谢紊乱。在所有血清脂质中,脂蛋白(a)[Lp(a)]与肾功能损害的相关性最显著。此外,单因素 logistic 回归显示,Lp(a)水平升高与 DN 的发生风险增加相关。在调整年龄、性别、T2DM 病程、BMI、SBP、DBP 和降脂药物使用等混杂因素后,Lp(a)水平与 DN 的发病风险呈独立正相关[比值比(OR):1.115,95%置信区间(CI):1.079-1.151,=6.06×10]。

结论:总体而言,我们发现血清 Lp(a)水平与 DN 的发生风险呈显著正相关,表明 Lp(a)可能成为诊断和治疗糖尿病肾病的有前途的靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/11f4/10822945/b2c776eb2350/fendo-14-1337469-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/11f4/10822945/fdd5ee953da4/fendo-14-1337469-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/11f4/10822945/b2c776eb2350/fendo-14-1337469-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/11f4/10822945/fdd5ee953da4/fendo-14-1337469-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/11f4/10822945/b2c776eb2350/fendo-14-1337469-g002.jpg

相似文献

[1]
Association between Lipoprotein(a) and diabetic nephropathy in patients with type 2 diabetes.

Front Endocrinol (Lausanne). 2023

[2]
Association between lipoprotein(a) plasma levels and diabetic nephropathy in Han Chinese patients with type 2 diabetes mellitus.

PLoS One. 2024

[3]
The diagnostic value of lipoprotein-associated phospholipase A2 in early diabetic nephropathy.

Ann Med. 2023

[4]
Association Between Lipoprotein (A) and Diabetic Nephropathy in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis.

Front Endocrinol (Lausanne). 2021

[5]
Risk factors for diabetic nephropathy complications in community patients with type 2 diabetes mellitus in Shanghai: Logistic regression and classification tree model analysis.

Int J Health Plann Manage. 2019-7-31

[6]
Serum Lipoprotein(a) and High-Density Lipoprotein Cholesterol Associate with Diabetic Nephropathy: Evidence from Machine Learning Perspectives.

Diabetes Metab Syndr Obes. 2023-6-22

[7]
Association of diabetic nephropathy with the severity of obstructive sleep apnea-hypopnea syndrome in patients with type 2 diabetes mellitus.

Endocr J. 2020-5-28

[8]
[The role of intravoxel incoherent motion diffusion-weighted imaging in distinguishing diabetic nephropathy from non-diabetic renal disease in diabetic patients].

Zhonghua Nei Ke Za Zhi. 2023-11-1

[9]
Investigation of angiotensin-1 converting enzyme 2 gene (G8790A) polymorphism in patients of type 2 diabetes mellitus with diabetic nephropathy in Pakistani population.

PLoS One. 2022

[10]
Serum lipoprotein(a) levels and diabetic nephropathy among Japanese patients with type 2 diabetes mellitus.

J Diabetes Complications. 2016-7

引用本文的文献

[1]
Exploring the impact of high rosuvastatin plasma exposure on new-onset diabetes mellitus: insights from machine learning-based prediction.

Eur J Med Res. 2025-8-25

[2]
Association between non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) and diabetic kidney disease in patients with diabetes in the United States: a cross-sectional study.

Lipids Health Dis. 2024-9-27

本文引用的文献

[1]
Lipoprotein(a) and carotid intima-media thickness in children with familial hypercholesterolaemia in the Netherlands: a 20-year follow-up study.

Lancet Diabetes Endocrinol. 2023-9

[2]
Study on the relationship between lipoprotein (a) and diabetic kidney disease.

J Diabetes Complications. 2023-1

[3]
Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease.

N Engl J Med. 2022-11-17

[4]
Association Between Lipoprotein (A) and Diabetic Nephropathy in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis.

Front Endocrinol (Lausanne). 2021

[5]
Worldwide Epidemiology of Diabetes-Related End-Stage Renal Disease, 2000-2015.

Diabetes Care. 2021-1

[6]
Serum lipoprotein (a) associates with a higher risk of reduced renal function: a prospective investigation.

J Lipid Res. 2020-10

[7]
Lipoprotein(a) plasma levels are not associated with incident microvascular complications in type 2 diabetes mellitus.

Diabetologia. 2020-6

[8]
Lipoprotein(a) the Insurgent: A New Insight into the Structure, Function, Metabolism, Pathogenicity, and Medications Affecting Lipoprotein(a) Molecule.

J Lipids. 2020-2-1

[9]
Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.

Lancet. 2020-2-13

[10]
The Global Burden of Diabetic Kidney Disease: Time Trends and Gender Gaps.

Curr Diab Rep. 2019-3-2

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索